Moderna

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards. The weak price action in the pharmaceutical giants is likely due to very bearish action in the general...

The year 2021 has featured retail trading-induced short squeezes, soaring special purpose acquisition companies (SPACs) and extreme volatility in cryptocurrency markets. Amid the many bouts of short-term mania, there are a handful of stocks in the S&P 500 Index that...

On Sunday, President Joe Biden's Chief Medical Adviser Dr. Anthony Fauci said officials would soon get the regulatory clearance to administer Covid-19 vaccine booster shots made by Pfizer Inc (NYSE: PFE). However, the Moderna Inc (NASDAQ: MRNA) booster could take a little...

This weekend's Barron's cover story examines the long-term prospects for big tech companies currently in the sights of regulators and lawmakers. Other featured articles discuss what the ongoing COVID-19 threat means for drugmakers and why investors so often fail to understand how to value...

Besides proudly stating that its Covid-19 shot produced a "robust" antibody response against the highly contagious delta variant last Thursday, Moderna (NASDAQ: MRNA) also posted second-quarter financial results that beat Wall Street's expectations on both earnings and revenue. Q2...

And so begins the month of August. The dog days of summer. Beaches, mountains, and lazy afternoons.If you follow the financial markets, that thinking might be jumping the gun, as there’s still plenty of action ahead. Although last week was arguably the height of earnings season, with releases...

These days, Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are swimming in real money and they have COVID-19 to thank. Since the beginning of April, Moderna and BioNTech (NASDAQ: BNTX) saw their shares go up about 80% and 100%, respectively. Much of that climb has been on the assumption...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Last week's bullish calls included the iPhone maker and top automakers. Bank stocks, a vaccine maker and a leading miner were among the bearish calls seen. In the wake of the Independence Day holiday,...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The past week's bullish calls included the e-commerce leader, a top biotech and the airlines. The iPhone maker, the top cryptocurrency and a COVID-19 vaccine maker were among the bearish calls seen. The...

It’s been more than a week since Technology finished in the green. Tech stocks rose in pre-market trading, but can they maintain those early gains? That’s one question hanging over Wall Street today.  We’ll talk more about the trauma in Tech lower down. First, let’s...

This weekend's Barron's cover story presents the results of the latest Barron's Big Money Poll. Other featured articles show which food stocks are worth bite and which real estate stocks have room to run. Also, see the prospects for a high-profile biotech, a logistics play, a video...

The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) handed down a recommendation to pause the use of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine. In a joint audio press conference hosted by Acting FDA Commissioner Janet Woodcock,...

This weekend's Barron's cover story explores one enterprise software company's transformation into a cloud giant. Other featured articles discuss who dominates the public cloud, who stands to benefit as Texas rebuilds and how to tell when tech companies are overvalued. Also, the...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The week's bullish calls included the e-commerce, electric vehicle and online sports betting leaders. A COVID-19 vaccine maker and a struggling retailer were among the bearish calls seen. February...